Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced (.
10 / 21 / 2022

Journal of Hemathology & Oncology, 2022 October 21
10 / 21 / 2022
09 / 12 / 2022
Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
Journal of Hematology & Oncology, 2022, October 27
Mariella Spalato‑Ceruso, Fanny Bouteiller, Jean‑Philippe Guegan, Maud Toulmonde, Alban Bessede, Michèle Kind, Sophie Cousin, Xavier Buy, Jean Palussiere, François Le Loarer, Berengere Dadone‑Montaudie, Marina Pulido and Antoine Italiano
05 / 26 / 2022
Nature medicine, 2022, May 26
A. Italiano , A. Bessede, M. Pulido, E. Bompas , S. Piperno-Neumann, C. Chevreau, N. Penel, F. Bertucci, M. Toulmonde, C. Bellera, J. P. Guegan, C. Rey, C. Sautès-Fridman , A. Bougoüin, C. Cantarel, M. Kind, M. Spalato, B. Dadone-Montaudie, F. Le Loarer, J. Y. Blay and W. H. Fridman
02 / 22 / 2022
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
Journal for ImmunoTherapy of Cancer, 2022, Feb 22